Axsome Therapeutics heads into its August 3 earnings print having shed 11% over the past month, with short sellers quietly adding pressure even as the analyst community stays firmly bullish.
The most telling shift in positioning is in short interest, which has jumped 16% over the past week to reach 6.1% of the free float — a meaningful acceleration that stands out against an otherwise quiet borrow market. Despite that build, borrow conditions remain extraordinarily loose: availability is running at roughly 8,900% of short interest, meaning there is essentially no friction for new shorts entering the trade. Cost to borrow has actually fallen sharply, down 29% on the week to just 0.25%, so bears face no financial penalty for holding their positions into the print. Options positioning offers little by way of additional alarm — the put/call ratio at 0.81 is slightly below its 20-day average of 0.83, suggesting options traders are not rushing to hedge ahead of the release.
The bull case rests on pipeline breadth. Analysts are near-unanimous in their bullishness, with the consensus price target implying roughly 30% upside from the current $218 price. BMO Capital initiated coverage this week at Outperform with a $310 target, while Mizuho trimmed slightly to $306 but kept its Outperform rating. The bears' concern is less about the stock's direction and more about timing: Auvelity's commercial launch for Alzheimer's Disease Agitation was delayed to mid-2026, solriamfetol remains pre-approval across its main indications, and the pipeline is burning cash through multiple Phase 3 programmes simultaneously. EPS momentum ranks in the 97th and 98th percentile on 30- and 90-day windows, and the analyst recommendation differential scores in the 93rd percentile — but the stock is priced for execution, and execution has been slower than hoped.
The institutional picture adds a note of caution from within. CEO Herriot Tabuteau sold nearly $12 million in shares on July 1, following a nearly identical $12 million sale on June 9. CFO Nick Pizzie also sold close to $8 million in June. Together, insiders recorded roughly $38.7 million in net sales over the past 90 days — consistent, sizeable, and concentrated at the C-suite level. The top holder, Antecip Capital, holds 14.3% of shares and made no change in its last reported period. BlackRock and Fidelity both added meaningfully in the most recent quarter.
The August 3 print is therefore less a test of whether Axsome's pipeline is promising — the Street already believes it is — and more a test of whether commercial revenue and clinical execution can justify a stock that, despite its recent slide, still trades at 88x trailing earnings and 150x EV/EBITDA.
See the live data behind this article on ORTEX.
Open AXSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
